Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

Abstract Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was...

Full description

Bibliographic Details
Main Authors: Jie Xu, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, Jian Hou, Zhu Chen, Wan-Hong Zhao, Ai-Li He, Jian-Qing Mi, Sai-Juan Chen
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Hematology & Oncology
Subjects:
LCAR-B38M
CAR T-cell therapy
Relapsed and refractory multiple myeloma
Long-term follow-up
Long-persisting CAR T cell
Online Access:https://doi.org/10.1186/s13045-024-01530-z

Internet

https://doi.org/10.1186/s13045-024-01530-z

Similar Items